glp 1 approval China Approves World First cAMP Biased One Receptor Agonist For Type Two Diabetes FDA-Approved Dosages and Indications for

GLP-1 receptor agonists (semaglutide and liraglutide) and tirzepatide carry a boxed warning about thyroid C-cell tumors in rodents and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

While bacteriostatic water is generally well-tolerated, repeated daily exposure over months could potentially affect the nasal lining

Y.JainS.et al (2012)

In terms of the primary outcome of reduction in A1C from baseline, although the 3-mg oral semaglutide group did not demonstrate superiority to sitagliptin 100 mg at 26 weeks, the 7-mg and 14-mg dosage groups did demonstrate statistically significant reductions in A1C from baseline when compared with sitagliptin